Volatility to Continue for Amarin (AMRN) with No NCE Decision, But Serious Upside Exists - Jefferies

Go back to Volatility to Continue for Amarin (AMRN) with No NCE Decision, But Serious Upside Exists - Jefferies

Groundhog Day for Amarin (AMRN); MKM Not Positive on NCE Status Although Company Remains Upbeat

November 19, 2012 10:42 AM EST

Analysts at MKM Partners commented on Amarin Corporation (NASDAQ: AMRN) after the FDA updated the Orange Book for October and once again failed to rule on NCE status for Vascepa.

MKM's Jon LeCroy notes this is the fourth delay and he assumes that it is unlikely that Amarin will be able to successfully petition the FDA to grant Vascepa NCE status. However,... More

Amarin Corp (NASDAQ: AMRN) NCE status isn't update in FDA Orange Book for October

November 16, 2012 2:18 PM EST

Amarin Corp (NASDAQ: AMRN) NCE status isn't update in FDA Orange Book for October.... More

Amarin (AMRN) Sees Downside Action

November 16, 2012 1:22 PM EST

Amarin Corporation plc (NASDAQ: AMRN) sees downside. NCE decision expected soon.... More